Share Buyback & Completion of Buyback Programme
EKF Diagnostics Holdings plc has successfully completed its share buyback programme, purchasing a total of 17,130,678 ordinary shares at a weighted average cost of 26.14 pence per share. The most recent transaction on January 30, 2026, involved the acquisition of 159,000 shares at an average price of 25.6875 pence, with these shares to be held in treasury. Following these purchases, the company's total voting rights stand at 431,963,112. Notably, a portion of the buyback involved 47,000 shares acquired from entities associated with Non-Executive Director Christopher Mills, ensuring his indirect beneficial interest remains below 30%.
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
Share Buyback
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 159,000 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 25.6875 pence per share. The Ordinary Shares purchased will be held in treasury.
This transaction marks the successful conclusion of the share buyback programme announced on 21 May 2025 and the subsequent extension as set out in the announcement on 21 October 2025. Pursuant to the share buyback programme, a total of 17,130,678 ordinary shares were purchased at a weighted average cost of 26.14 pence per Ordinary Share.
Aggregated information
| Date of purchase | 30 January 2026 | ||
|---|---|---|---|
| Number of Ordinary Shares purchased | 159,000 | ||
| Highest price paid per Ordinary Share | 25.8000p | ||
| Lowest price paid per Ordinary Share | 25.5000p | ||
| Volume weighted average price paid | 25.6875p | ||
| Transaction details | |||
| Number of Ordinary Shares purchased | Transaction price (GBp) | Time of transaction | Trading venue |
| 25,000 | 25.8000p | 10:10:25 | AIMX |
| 45,000 | 25.8000p | 11:44:21 | AIMX |
| 42,000 | 25.5000p | 11:51:53 | AIMX |
| 47,000 | 25.6875p | 15:37:38 | AIMX |
Total voting rights
Following the purchase, the Company's total issued share capital will consist of 435,383,092 Ordinary Shares, of which 3,419,980 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 431,963,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
PDMR dealing
As part of the buyback and within the above aggregate purchase, EKF acquired 47,000 Ordinary Shares in total at a price of 25.6875 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("Oryx") and North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). EKF acquired 15,667 and 31,333 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.
Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 127,381,000 Ordinary Shares.
Additional disclosures relating to this PDMR dealing are detailed below.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com | |
| Julian Baines, Executive Chair | via Walbrook PR | |
| Gavin Jones, Chief Executive Officer | ||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 | |
| Phil Davies / Patrick Weaver | ||
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com | |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 | |
| a) | Name | Christopher Mills |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | EKF Diagnostics Holdings plc |
| b) | LEI | 213800DXTF3EAUK1AR05 |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of 1 pence each |
| Identification code | GB0031509804 | |
| b) | Nature of the transaction | Disposal of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| 25.6875p | 47,000 | |
| d) | Aggregated information | |
| - Aggregated volume | n/a | |
| - Price | ||
| e) | Date of the transaction | 30 January 2026 |
| f) | Place of the transaction | London Stock Exchange, AIMX |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.